New hope for tough esophageal cancer: drug duo targets tumors

NCT ID NCT05022654

First seen Oct 31, 2025 · Last updated May 16, 2026 · Updated 30 times

Summary

This study tests a new drug combination (SI-B001 plus irinotecan) in 22 adults with advanced esophageal cancer that has returned or spread and no longer responds to standard treatments. The goal is to see if the combo can shrink tumors or slow the disease. Participants receive the drugs intravenously and are monitored for safety and effectiveness.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ESOPHAGEAL SQUAMOUS CELL CARCINOMAS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Anyang Cancer Hospital of Henan Province

    Anyang, Henan, China

  • Beijing Cancer Hostital

    Beijing, Beijing Municipality, 100142, China

  • Shanxi Cancer Hospital

    Taiyuan, Shanxi, China

  • Suining Central Hospital

    Suining, Sichuan, China

  • The First Affiliated Hospital of Henan University of Science and Technology

    Luoyang, Henan, China

  • Xuzhou Central Hospital

    Xuzhou, Jiangsu, China

Conditions

Explore the condition pages connected to this study.